- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC in the Press, August 26, 2016
A review of our peer-reviewed research, in the healthcare and mainstream press.
Studies from the current issue of The American Journal of Managed Care have been cited frequently this week.
New research from the CVS Health Research Institute was one of the most-cited articles this week. The study found that interventions to keep patients with common chronic conditions on their medication are very cost effective, especially if those interventions target patients who take 3 or more medications. Payers can save between $38 million and $63 million per 100,000 members by focusing on these patient populations. Multiple outlets cited the study, including The Pharmacist, the official publication of the American Pharmacist Association.
In addition, the Center for Infectious Disease Research and Policy at the University of Minnesota discussed an article by CDC authors, who found that more than three-fourths of adults diagnosed as having bronchitis receive an antibiotic, even though antibiotics are not indicated for this condition.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
